Gil Blum

Kaveri Pohlman

Marc Frahm

- Shattuck Labs, Inc. closed a private placement of up to **$103 million**, with proceeds expected to fund operations into **2029** assuming full exercise of common stock warrants.  **[1680367_0001193125-25-188078_d95844dex991.htm:0]** 
- The financing is anticipated to advance SL-325 through multiple Phase 2 clinical trials, including for Inflammatory Bowel Disease (IBD).  **[1680367_0001193125-25-188078_d95844dex991.htm:0]** 
- The company appointed **Daniel Baker, M.D.**, and **Mona Ashiya, Ph.D.**, to its Board of Directors, while **Tyler Brous, Carrie Brownstein, M.D., Michael Lee, and Kate Sasser, Ph.D.**, resigned.  **[1680367_0001193125-25-188078_d95844d8k.htm:0]** **[1680367_0001193125-25-188078_d95844dex991.htm:0]** **[1680367_0001193125-25-188078_d95844d8k.htm:1]**

Shattuck Labs (STTK)